Bicyclic compound and use thereof for medical purposes

Patent metadata

Field	Value
Publication number	US-9388157-B2
Application number	US-201414587829-A
Country	US
Kind code	B2
Filing date	Dec 31, 2014
Priority date	Jul 28, 2009
Publication date	Jul 12, 2016
Grant date	Jul 12, 2016

Abstract

Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.

First claim

The invention claimed is:

1. A method of preparing a compound represented by the general formula (I):

wherein R 1 represents (1) COOH, (2) COOR 2 , (3) CH 2 OH, or (4) CONR 3 R 4 ; R 2 represents a C1-C6 alkyl group optionally substituted with a hydroxy group, ONO 2 or a C1-4 alkoxy group; R 3 and R 4 each represent independently a hydrogen atom, or a C1-4 alkyl group optionally substituted with ONO 2 ; R 5 represents a halogen atom, a hydroxy group, or a C1-4 alkoxy group; Z represents (1) —(CH 2 ) m —, (2) —(CH 2 ) n —CH═CH—, (3) —(CH 2 ) p -A-CH 2 —, or (4) ring 1; A represents an oxygen atom, or a sulfur atom; W represents a C1-6 alkyl group optionally substituted with 1 to 5 substituents selected from the group consisting of (1) a hydroxy group, (2) an oxo group, (3) a halogen atom, (4) a C1-4 alkyl group, (5) a C1-4 alkoxy group, (6) ring 2, (7) —O-ring 2, and (8) —S-ring 2, ring 1 and ring 2 each represent independently a C3-10carbocycle or a 3- to 10-membered heterocycle, optionally substituted with 1 to 5 substituents selected from the group consisting of (1) a halogen atom, (2) CF 3 , (3) OCF 3 , (4) a C1-4 alkoxy group, (5) a C1-4 alkyl group, (6) a hydroxy group, and (7) a nitrile group; m represents an integer of 1 to 6; n represents an integer of 1 to 4; p represents an integer of 1 to 4;

represents a single bond or a double bond;

represents α configuration;

represents β configuration; and

represents α configuration, β configuration or an arbitrary mixture thereof,
or a salt thereof;
wherein the method comprises:
reacting a compound represented by general formula (IIA) with a compound represented by general formula (IIA):

wherein T 1 represents a protective group for the hydroxy group and R 101 represents a C1-6 alkyl group,
if W represents a C1-6 alkyl group substituted with 1 to 5 oxo groups, then a step (2) of reducing the oxo group substituents of the C1-6 alkyl group represented by W, and
a step (3) of deprotecting the reduced product of step (2) by removing the protective group.

2. The method of preparing a compound according to claim 1 , wherein the compound is represented by the general formula (I-1):

wherein all symbols represent the same meanings as those described in claim 1 ,
or a salt thereof.

3. The method of preparing a compound according to claim 2 , wherein the compound is represented by general formula (I-2):

wherein R 6 and R 7 each represent independently a hydrogen atom, a hydroxy group, a halogen atom, a C1-4 alkyl group or a C1-4 alkoxy group; R 6 and R 7 may be taken together to form an oxo group; Y represents —CH 2 —, —O— or —S—; and other symbols represent the same meanings as those described in claim 2 ,
or a salt thereof.

4. The method of preparing a compound according to claim 3 , wherein the ring 2 is a C3-7 carbocycle, or a salt thereof.

5. The method of preparing a compound according to claim 3 , wherein Z is (1) —(CH 2 ) m —, or (2) —(CH 2 ) p -A-CH 2 —; and all symbols represent the same meanings as those described claim 2 ,
or a salt thereof.

6. The method of preparing a compound according to claim 3 , wherein the compound represented by the general formula (I-2) is a compound selected from:
(1) 4-{(3S, 5aR, 6R, 7R, 8aS)-7-hydroxy-6-[(1E,3R)-3-hydroxy-4-phenoxy-1-buten-1-yl]octahydro-2H-cyclopenta[b]oxepin-3-yl}butanoic acid,
(2) ethyl 4-{(3S, 5aR, 6R, 7R, 8aS)-7-hydroxy-6-[(1E,3R)-3-hydroxy-4-phenoxy-1-buten-1-yl]octahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate,
(3) 2-propanyl 4-{(3S, 5aR, 6R, 7R, 8aS)-7-hydroxy-6-[(1E,3R)-3-hydroxy-4-phenoxy-1-buten-1-yl]octahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate,
(4) 4-{(3S, 5aR, 6R, 7R, 8aS)-6-[(1E,3R)-4-(3-chlorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoic acid,
(5) 2-propanyl 4-{(3S, 5aR, 6R, 7R, 8aS)-6-[(1E,3R)-4-(3-chlorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate,
(6) 4-{(3S, 5aR, 6R, 7R, 8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoic acid, and
(7) 2-propanyl 4-{(3S, 5aR, 6R, 7R, 8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate,
or a salt thereof.

7. The method of preparing a compound according to claim 1 , wherein the deprotecting step (3) is carried out by a reaction selected from a reaction by alkali hydrolysis, a reaction under acidic conditions, a reaction by hydrogenation degradation, a reaction of a silyl group, a reaction using a metal, and a reaction using a metal complex.

Assignees

• Ono Pharmaceutical Co
• Ono Pharmaceutical Co

Inventors

• Kambe Tohru
• Maruyama Toru
• Yamane Shinsaku
• Nakayama Satoshi
• Tani Kousuke

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P27/10

  for accommodation disorders, e.g. myopia · CPC title

• A61P27/12

  for cataracts · CPC title

• A61P27/06

  Antiglaucoma agents or miotics · CPC title